RC48
Phase 2Small molecule
RC48 is one of 66 small molecule programs targeting Ovarian Carcinoma. It is currently in Phase 2.
5
Indications
8
Total Trials
7
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
181 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Taxotere
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Avastin
RochePhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Beyfortus
BeiGenePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment Failure2 trials
Gastric Cancer2 trials
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07474324·124 enrolled
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06385873·32 enrolled
Non-Small Cell Lung Cancer1 trial
Second-line Treatment1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RC48. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details